TG Therapeutics to Participate in the Jefferies London Healthcare Conference

Rhea-AI Summary

TG Therapeutics (NASDAQ: TGTX) announced that its Executive Chairman and CEO, Michael S. Weiss, will host a fireside chat during the Jefferies London Healthcare Conference on November 18-19, 2021. The chat will be available for on-demand download starting at 8:00 AM GMT / 3:00 AM ET on November 18. Investors can access the discussion on the company's website for 30 days post-event. The company focuses on treatments for B-cell malignancies and autoimmune diseases, with ongoing Phase 3 programs for multiple sclerosis and chronic lymphocytic leukemia.

Fireside chat available for on demand download at 5:00 PM GMT/ 3:00 AM ET on Thursday November 18, 2021

NEW YORK, Nov. 15, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will participate in a fireside chat during the Jefferies London Healthcare Conference, taking place virtually November 18 – 19, 2021.

The fireside chat will be available for on demand download through the Jefferies conference platform beginning at 8:00am GMT / 3:00am ET on Thursday, November 18, 2021. The fireside chat will also be available on the Events page, located within the Investors & Media section, of the Company’s website at http://ir.tgtherapeutics.com/events, beginning on November 18, 2021 and for a period of 30 days after the event.

ABOUT TG THERAPEUTICS, INC.

TG Therapeutics is a fully-integrated, commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. In addition to an active research pipeline including five investigational medicines across these therapeutic areas, TG has received accelerated approval from the U.S. FDA for UKONIQ® (umbralisib), for the treatment of adult patients with relapsed/refractory marginal zone lymphoma who have received at least one prior anti-CD20-based regimen and relapsed/refractory follicular lymphoma who have received at least three prior lines of systemic therapies. Currently, the Company has three programs in Phase 3 development for the treatment of patients with relapsing forms of multiple sclerosis (RMS) and patients with chronic lymphocytic leukemia (CLL) and several investigational medicines in Phase 1 clinical development. For more information, visit www.tgtherapeutics.com, and follow us on Twitter @TGTherapeutics and Linkedin.

UKONIQ® is a registered trademark of TG Therapeutics, Inc.

CONTACT:
	Investor Relations Email: ir@tgtxinc.com Telephone: 1.877.575.TGTX (8489), Option 4
	Media Relations: Email: media@tgtxinc.com Telephone: 1.877.575.TGTX (8489), Option 6

FAQ

When will TG Therapeutics' fireside chat take place?

The fireside chat will occur on November 18, 2021, during the Jefferies London Healthcare Conference.

How can I access the TG Therapeutics fireside chat?

The chat will be available for on-demand download starting at 8:00 AM GMT / 3:00 AM ET on November 18, 2021, on the company's website.

What is the focus of TG Therapeutics?

TG Therapeutics specializes in developing treatments for B-cell malignancies and autoimmune diseases.

What investigational medicines is TG Therapeutics developing?

TG Therapeutics has five investigational medicines for B-cell malignancies and autoimmune diseases, along with three Phase 3 programs for multiple sclerosis and chronic lymphocytic leukemia.

What is UKONIQ and its significance for TG Therapeutics?

UKONIQ® (umbralisib) is an FDA-approved treatment for specific types of lymphoma, marking TG Therapeutics' entry into the market for B-cell malignancies.